The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

People invited to undergo FIT were more likely to participate in colorectal cancer screening compared with those invited to undergo colonoscopy. FIT was noninferior to colonoscopy for colorectal ...

Multitarget stool DNA tests — which are becoming more popular in the United States — have shown increased sensitivity over fecal immunochemical tests (FITs) for early colorectal cancer (CRC) screening ...

Regular preventive screenings can make a life-changing difference—especially when it comes to cancer. According to the American Cancer Society, colorectal cancer is the third-leading cause of ...

An at-home FIT test (Fecal Immunochemical Test) is one of the easiest ways to screen for colon cancer. This short explainer video shows who needs a FIT test, how it works, and how to ask your doctor ...

A mailed fecal immunochemical test (FIT) outreach followed by patient navigation for those with a positive test increased colorectal cancer (CRC) screening participation at 6 months compared with ...

Pharmacy-based CRC screening programs using FIT can improve early detection, especially in underserved communities, with effective follow-up care. Patients prefer digital updates for negative results ...

March marks Colorectal Cancer Awareness Month, a time health experts say is critical for encouraging people to get screened ...

Please provide your email address to receive an email when new articles are posted on . People in rural areas experience a variety of barriers to CRC screening. A mailed fecal immunochemical test ...

Colon cancer is the second-deadliest cancer in the US, partly due to low screening rates. New and emerging screening tools, like blood and breath tests, may offer alternatives to in-office screenings.

Colon cancer is the second-deadliest cancer in America. It's not deadly because it's particularly hard to treat or because oncologists are bad at spotting it. In large part, it's because people aren't ...